FIELD: medicine.
SUBSTANCE: invention relates to a compound of the formula I having properties of fucosidase enzyme inhibitors and its use for the treatment of tumor or cancer disease, which is liver cancer. In the general formula I, X1, X2 and X3 are OH; R is C1-3alkyl; R1 is H; R2 is selected from a group consisting of -NRbC(O)Ra, and -C(O)NRbRa; Ra is 
; and Rb is H.
EFFECT: obtaining fucosidase inhibitors.
(I)
8 cl, 3 dwg, 9 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MONOCLONAL ANTIBODIES AGAINST CLAUDIN 1 FOR PREVENTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA | 2016 |
|
RU2770021C2 |
| METHODS OF TREATING CANCER USING ACTIVATED T-CELLS | 2016 |
|
RU2729362C2 |
| COMPOSITIONS AND METHODS OF TREATMENT OF LIVER CANCER | 2018 |
|
RU2802962C2 |
| CANCER MODELS AND CORRESPONDING METHODS | 2014 |
|
RU2707531C2 |
| CANCER TREATMENT WITH TG02 | 2017 |
|
RU2749025C2 |
| METHOD OF PREDICTING EFFICIENCY OF RAR-α AGONIST | 2006 |
|
RU2405447C2 |
| COMPOSITION OF COMPOUNDS AND WAYS OF THEIR APPLICATION | 2015 |
|
RU2659068C1 |
| INHIBITORS OF CELL CYCLE CHECKPOINT KINASE 1 FOR AMPLIFICATION OF DNA-DAMAGING AGENTS | 2010 |
|
RU2567044C2 |
| USE OF EP4 RECEPTOR ANTAGONISTS FOR TREATMENT OF NASH-ASSOCIATED LIVER CANCER | 2017 |
|
RU2717331C2 |
| USE OF EP4 RECEPTOR ANTAGONISTS FOR TREATMENT OF NASH-ASSOCIATED LIVER CANCER | 2017 |
|
RU2762193C2 |
